UBS AM
EWTX icon

UBS AM’s Edgewise Therapeutics EWTX Stock Holding History

UBS AM’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.8M Buy
118,209
+3,489
+3% +$120K ﹤0.01% 1628
2026
Q1 		$3.61M Buy
114,720
+16,657
+17% +$480K ﹤0.01% 1737
2025
Q4 		$2.43M Sell
98,063
-41,049
-30% -$824K ﹤0.01% 1809
2025
Q3 		$2.26M Sell
139,112
-52,494
-27% -$745K ﹤0.01% 1700
2025
Q2 		$2.51M Sell
191,606
-81,251
-30% -$1.17M ﹤0.01% 2045
2025
Q1 		$6M Sell
272,857
-6,268
-2% -$164K ﹤0.01% 1482
2024
Q4 		$7.45M Buy
279,125
+194,831
+231% +$6.2M ﹤0.01% 1398
2024
Q3 		$2.25M Buy
84,294
+4,426
+6% +$88K ﹤0.01% 1976
2024
Q2 		$1.44M Buy
79,868
+47,455
+146% +$828K ﹤0.01% 2172
2024
Q1 		$591K Buy
32,413
+8,800
+37% +$140K ﹤0.01% 2232
2023
Q4 		$258K Buy
+23,613
New +$166K ﹤0.01% 2456

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS AM's EWTX Position: Q2 2026 in Review

UBS AM increased its Edgewise Therapeutics (EWTX) stake by 3% in Q2 2026, buying an estimated $120K and bringing the position to 118,209 shares worth $4.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1628.

UBS AM first reported a position in EWTX in Q4 2023 and has held it in 11 quarters since. The position peaked at $7.45M in Q4 2024. 223 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • UBS AM held 118,209 shares of Edgewise Therapeutics worth $4.8M as of Q2 2026.
  • UBS AM bought 3,489 Edgewise Therapeutics shares in Q2 2026, an estimated $120K.
  • Edgewise Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1628 holding.
  • UBS AM first reported a position in Edgewise Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • UBS AM's Edgewise Therapeutics position peaked at $7.45M in Q4 2024.
  • 223 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.